The Centre, in a written advisory to the chief secretaries of states and administrators of union territories, recommended on March 22 that the interval between two doses of Oxford-AstraZeneca’s COVID-19 vaccine Covishield, be increased.
India’s drug regulator has approved two vaccines for emergency use – Covishield, which is being manufactured by the Serum Institute of India, and Bharat Biotech's Covaxin.
The Centre’s advice to increase the gap between two doses of COVID-19 vaccine from four to six weeks to six to eight weeks, however, pertains only to Covishield and not Covaxin.
Explaining the reason behind the advisory, the central government said that the National Technical Advisory Group on Immunization (NTAGI) and the National Expert Group on Vaccine Administration have advised increasing the current interval period being followed in India citing scientific evidence.
Evidence has emerged showing enhanced protection if the second dose of Covishield is delayed by six weeks and more, but not exceeding the stipulated period of eight weeks.
Besides, Oxford-led clinical trials have confirmed that the Covishield vaccine has 76 percent efficacy three weeks after the first dose that, which increases up to 82 percent if the inter-dose interval is increased to 12 weeks or more.
The study also stated that the COVID-19 vaccine efficacy dipped to only 54.9 percent, if the two doses are given less than six weeks apart.
Follow our coverage of the coronavirus crisis here
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!